Boehringer Ingelheim oral thrombin inhibitor granted CE Mark
The European Commission has granted marketing authorization to Boehringer Ingelheim for its oral direct thrombin inhibitor, Pradaxa (dabigatran etexilate) in all 27 EU member states.
Boehringer said it anticipates that Pradaxa will be launched in Germany and the United Kingdom in the coming weeks.
Pradaxa is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery, according to the Ingelheim, Germany-based company.
“This first license for our novel oral anticoagulant Pradaxa marks an important advance and milestone in anticoagulation therapy and the prevention of potentially fatal thrombi, or blood clots,” said Andreas Barner, MD, Boehringer board member, who is responsible for research, development and medicine.
Boehringer said it anticipates that Pradaxa will be launched in Germany and the United Kingdom in the coming weeks.
Pradaxa is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery, according to the Ingelheim, Germany-based company.
“This first license for our novel oral anticoagulant Pradaxa marks an important advance and milestone in anticoagulation therapy and the prevention of potentially fatal thrombi, or blood clots,” said Andreas Barner, MD, Boehringer board member, who is responsible for research, development and medicine.